Halia Therapeutics

Halia Therapeutics is a biotechnology company developing therapies through a research approach it calls genetic resilience. Rather than focusing only on what causes disease, Halia studies why some people remain healthy despite genetic or environmental risks. It analyzes large-scale family pedigrees, health records, and genomic data to identify protective genetic factors and translate them into potential drug targets.

The company’s GENMOR platform compares families in which relatives have different disease outcomes, helping researchers uncover resilience-associated variants such as RAB10. GENMOR-AI supports this work by integrating genomic and phenomic data, modeling biological interactions, and prioritizing promising resilience factors.

Halia’s clinical programs focus on Alzheimer’s disease and inflammation-related conditions, including MDS, while its research also spans obesity, neurology, metabolism, and oncology. Its programs include HT-4253, which targets protective variants associated with Alzheimer’s resilience, and HT-6184, based on research into NEK7 inhibition. In preclinical models, HT-6184 enhanced semaglutide’s weight-loss effect while preserving lean mass. Halia aims to turn insights from naturally resilient individuals into therapies for broader patient populations.